E-DRUG: Dipyrone in Sweden

[Alec Walker <amwalker@episun1.harvard.edu>]

E-DRUG: Dipyrone in Sweden
--------------------------
Dear Colleagues:

Dipyrone has been reapproved in Sweden. I do not have 
details about this. I wrote to Carlos Martinez of 
Hoechst Marion Roussel (the major manufacturers of 
dipyrone). Here is the relevant portion of his reply:

"As a result of the reevaluation of the risk profile of 
dipyrone, it was submitted in Sweden. The indications 
claimed in the submission were postoperative pain and colic 
pain. In 1995, dipyrone was reapproved the indications 
claimed. Dipyrone has not been submitted for approval
in countries other than Sweden."

Perhaps others may have more information. Regards,

Alec

Alexander M. Walker,MD, DrPH
Department of Epidemiology
Harvard School of Public Health
677 Huntington Ave 
Boston MA 02115, USA
Email: amwalker@episun1.harvard.edu

Note from the moderator:
------------------------
It would be interesting to know the background of the
reapproval of dipyrone in Sweden. Was this decision based
on any new data? Is dipyrone first line therapy for the
approved indications in Sweden? Perhaps folks familiar 
with the issue (Sten Olsson at the WHO Collaborating 
Center for International Drug Monitoring in Sweden or 
others) would provide some feedback to e-druggers. Thanks.

Syed Rizwanuddin Ahmad
Email: srahmad@essential.org
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-e-drug@usa.healthnet.org'.